Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
This post was originally published on this site